Strategy: Avego BioScience Capital

Antios Therapeutics

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Caribou Biosciences

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Ribon Therapeutics

Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.

Arch Oncology

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Immunocore

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021